Anti-IL-23A Antibody Dosing Schedule for Fewer Inflammatory Disease Treatments

The patent applies preliminary action by administering a loading dose before maintenance doses. This initial higher dose (e.g., 300 mg) is given to rapidly achieve therapeutic drug levels and clinical response, allowing subsequent maintenance doses to be spaced further apart (every 8-12 weeks). This resolves the contradiction by ensuring treatment effectiveness through the loading dose while reducing treatment complexity by enabling longer intervals between maintenance administrations.

The patent implements periodic action through structured dosing regimens with specific intervals. The treatment protocol specifies initial dosing followed by maintenance doses at predetermined intervals (e.g., weeks 4, 8, 12, then every 8-12 weeks). This periodic structure ensures therapeutic efficacy is maintained while reducing the overall number of administrations compared to continuous frequent dosing, thereby reducing patient burden and treatment complexity.

The loading dose serves as preliminary action that rapidly establishes therapeutic drug levels in the patient's system. By administering a higher initial dose (e.g., 300 mg) followed by lower maintenance doses, the treatment achieves clinical response quickly, maintaining therapeutic efficacy even with fewer total administrations. This resolves the contradiction by ensuring efficacy through the loading phase while simplifying the overall treatment regimen.

The patent applies parameter changes by varying the dose amount based on treatment phase. The loading dose uses a higher parameter value (300 mg) to rapidly achieve efficacy, while maintenance doses use lower values (90-180 mg) at extended intervals. This parameter variation ensures therapeutic effectiveness is achieved and maintained while reducing the total number of administrations, thereby improving treatment simplicity without compromising efficacy.